Recent and classical work has revealed biologically and medically significant subtypes in complex diseases and traits. However, relevant subtypes are often unknown, unmeasured, or actively debated, making automatic statistical approaches to subtype definition particularly valuable. We propose reverse GWAS (RGWAS) to identify and validate subtypes using genetics and multiple traits: while GWAS seeks the genetic basis of a given trait, RGWAS seeks to define trait subtypes with distinct genetic bases. Unlike existing approaches relying on off-the-shelf clustering methods, RGWAS uses a bespoke decomposition, MFMR, to model covariates, binary traits, and population structure. We use extensive simulations to show these features can be crucial for power and calibration. We validate RGWAS in practice by recovering known stress subtypes in major depressive disorder. We then show the utility of RGWAS by identifying three novel subtypes of metabolic traits. We biologically validate these metabolic subtypes with SNP-level tests and a novel polygenic test: the former recover known metabolic GxE SNPs; the latter suggests genetic heterogeneity may explain substantial missing heritability. Crucially, statins, which are widely prescribed and theorized to increase diabetes risk, have opposing effects on blood glucose across metabolic subtypes, suggesting potential have potential translational value.
Results

37
Reverse GWAS is calibrated and powerful in simulations 38 We simulate from the full MFMR model to assess RGWAS (Methods, Supplementary 39 Section 3). We add noise that is correlated across traits; large main subtype effects; and 40 a covariate matrix G containing null, homogeneous, and heterogeneous SNPs. We use 41 27 quantitative traits and 3 binary traits and simulate K = 2 subtypes (or K = 1). 42 We test several other methods to find subtypes in step 1 (Methods). First, we use 43 Gaussian Mixture Models (GMM) to represent covariate-unaware methods, e.g. 44 k-means [27, 30] and TDA [21, 25, 26] . Second, we use a new Canonical Correlation 45 Analysis (CCA) approach that defines the subtype vector z as the top phenotypic CC. 46 Third, we use the true z to show the best-case scenario with perfect subtyping (Oracle). 47 We then use z in the step 2 heterogeneity test, defined by (3), conditioning on the 48 main effects of z ( Figure 1 ). We aggregate 1,000 simulated datasets and, per dataset, 49 the quantitative traits and SNPs in each category. Binary traits give similar results 50 ( Supplementary Figure 2) . 51 RGWAS with MFMR is calibrated and almost perfectly obtains the oracle subtypes 52 (Supplementary Figure 3 ) and power ( Figure 1d ). Crucially, it remains calibrated even 53 when K = 1 (Figure 1b ), so RGWAS discoveries validate the existence of subtypes. 54 Further, when K > 2 subtypes were simulated, MFMR with fixed K = 2 lost power but 55 remained calibrated ( Supplementary Figure 4 ). 56 Conversely, GMM is miscalibrated by an order of magnitude when K = 1, making it 57 unreliable for subtype validation (Figure 1b ). GMM cannot distinguish covariate from 58 subtype, and it is inflated when homogenoues effects are stronger than heterogeneous 59 ( Figure 1c, Supplementary Figure 4 ). 60 CCA has low power but seems calibrated and, sometimes, to outperform the oracle 61 ( Supplementary Figure 4) . But this is a Pyrrhic victory: by smoothing over traits, CCA 62 causes bias, which adds signal for heterogeneous traits but inflates FPR (Supplementary 63 Figure 5 and Section 4). 64 We also tried the top phenotypic PC for z, which performed like a lower-power CCA 65 ( Supplementary Figure 1) . The top genetic PC [24] , instead, had very low power.
Null SNPs
(Covariates are ignored by methods like GMM.) Nonetheless, this distinction can be 74 unclear in practice, which we test by treating a covariate like a trait (or vice versa). 75 MFMR remained calibrated, unlike GMM (Supplementary Figure 6 ). 76 Finally, we simulated an even mixture of two populations and 10,000 SNPs from a 77 Balding-Nichols model with F ST = .1 (Supplementary Section 3.2). We repeated our 78 simulations using 12 simulated SNPs for G and adding population main effects of 79 varying strength. For MFMR and the oracle, we condition on three genetic PCs and 80 their interactions with z in step 2. MFMR remains calibrated and powerful while CCA 81 and GMM suffer substantial FPR inflation, even for completely null SNPs 82 (Supplementary Figure 2 ). Including PCs in step 2 after using GMM in step 1 can 83 partially reduce inflation, but only when subtypes are truly present.
84
RGWAS recovers known CONVERGE subtypes 85
Only one GWAS of clinical depression has reported replicated associations with major 86 depression (MD) [42] . A possible explanation for this lack of GWAS hits is genetic, 87 environmental, and/or diagnostic heterogeneity, suggesting RGWAS may be useful.
88
The CONVERGE study recruited and deeply phenotyped Han Chinese women with 89 recurrent MD and matched controls. Cases were carefully ascertained to minimize 90 environmental heterogeneity, comparatively amplifying biological heterogeneity. We 91 used N = 9, 303 samples measured on 31 binary and 10 quantitative traits. We 92 conditioned on an intercept, age, and ten genetic PCs as heterogeneous covariates. We 93 jointly imputed the covariates and traits (Methods). Quantatitative trait 90% inter-quantile ranges (a) and binary trait prevalences (b) are shown for each subtype. (c) Per-subtypes odds ratios (±2 s.e.) for two SNPs discovered by (homogeneous) GWAS [42] (left) and three SNPs discovered using known subtypes [43] (right). (d) Subtype sizes.
The inferred subtypes with K = 2 are summarized in Figure 2 . As expected, the 95 subtypes distinguish lifetime adversity: the aggregate measure "Stress" is split [43] . 96 October 17, 2018 4/18
We tested five SNPs for effect heterogeneity across subtypes ( Figure 2c ). The first 97 two (rs35936514 and rs12415800) were discovered in the initial GWAS [42] and we use 98 as negative controls for heterogeneity. For positive controls, we use three SNPs 99 (rs7526682, rs11577545, and rs950893) previously found to interact with "Stress" [43] .
100
As expected, the homogeneous SNPs are nearly genome-wide significant, and RGWAS 101 successfully assigns all five SNPs. The heterogeneous SNPs show only modest 102 homogeneous signal because they have essentially no effect in the "Stress" subtype. 103 We chose K = 2 using prior knowledge that MD can be split by (binary) stress. We 104 assessed this empirically by evaluating the MFMR likelihood on held-out data, which 105 supported K > 1 subtypes ( Supplementary Figure 7) . K = 3 creates an MD-only 106 subtype, so we do not pursue K ≥ 3.
107
New metabolic subtypes with genetic and pragmatic significance 108
We next applied RGWAS to metabolic traits measured in METSIM [44] . By combining 109 genetic, environmental, metabolomic, and disease measurements, METSIM allows 110 studying the pathway from risk factors to metabolic consequences to altered disease risk. 111 We studied 6,248 unrelated Finnish men. We used three binary traits: 854 samples 112 had T2D, 3,524 had pre-diabetes (preT2D), and 541 had coronary heart disease (CHD); 113 we excluded 15 samples with T1D. We used 13 quantitative traits, including 6 PCs of 114 228 nuclear magnetic resonance (NMR) metabolite measurements (capturing 77% of 115 variance). As covariates, we used three genetic PCs, age, age 2 , and smoking, alcohol, 116 statin, diuretic, and beta-blocker use. 117 We study K = 3 to compromise between parsimony and the cross-validated 118 log-likelihood, which broadly supports 1 < K ≤ 8 ( Supplementary Figure 7) . To test 119 robustness to perturbations, we used five-fold cross-validation. We found that 93% of 120 originally co-clustered pairs (i.e. same most likely subtype) remained together, showing 121 that people from the same population can be accurately assigned to existing subtypes. 122 The three inferred metabolic subtypes are summarized in Figure 3 . They primarily 123 distinguish the metabolomic PCs, which are aggregates of 228 NMR traits. To elucidate 124 the subtypes, we fit logistic regressions on the raw NMR traits, conditional on statin, 125 and studied those with nominal p < .01 (despite [27, 29] , these p-values are not 126 calibrated). We first compared the large blue group to the combined orange and green 127 groups, which suggested the blue group had less esterified cholesterol in small HDL and 128 higher histidine and relative amounts of omega-3 fatty acid. Next, comparing orange to 129 green indicated orange had more free but less esterified cholesterol, especially in large 130 LDL, and that orange has more polyunsaturated fats and phenylalanine.
131
Cluster Means and 90% IQR 
Genetic metabolic heterogeneity 132
To test for polygenic subtype heterogeneity, we first used IID GxEMM and found 133 significant subtype-specific heritability for 12/16 traits (p < .05/16, Figure 4 ), 134 biologically distinguishing the subtypes. Further, this analysis increases average 135 heritability estimates from 22.3% to 36.7% ( Supplementary Figure 8) , showing unknown 136 subtypes can mask substantial heritability. As fixed effects, we used subtype main 137 effects, age, age 2 , and three genetic PCs; for CHD, LDL, HDL, TG, and the NMR PCs, 138 we also included statin. Variance explained is calculated after residualizing fixed 139 effects [45] . The richer Free GxEMM fits significantly better than IID for 11/16 traits 140 (p < .05/16, Supplementary Figure 8 ) and suggests, on average across traits, that 141 orange and green subtypes have higher heritability than blue, which has roughly zero 142 specific heritability (Figure 3d ). HMGCR [47] ; it also interacts with an APOE SNP on fenofibrate response [48] .
153
rs7138803 interacts with exercise for obesity [49] and features in an obesity score 154 interacting with diet [50] . rs780094 interacts with another SNP for fasting glucose [51] , 155 suggestively interacts with diet [52] , broadly affects lipid levels, and is one of three 156 SNPs in a risk score interacting with postprandial and post-fenofibrate cholesterol [53] . 157 We next performed a genome-wide scan with the global, K df test (GxEWAS). This 158 cannot establish SNP heterogeneity, but it can increase power over GWAS when 159 heterogeneity exists. GxEWAS and GWAS give largely consistent results ( Table 1, 160 Supplementary Figure 9 ), as expected because the homogeneous and global tests are not 161 independent. Nonetheless, GxEWAS is a valuable complement to GWAS as it discovers 162 10 additional loci (though GxEWAS misses 19/60 GWAS loci).
163
To mimic prior approaches, we repeated the GxEWAS with covariate-unaware tests 164 and GMM subtypes. Genome-wide QQ-plots were highly inflated for K ∈ {2, 3, 4}
165
( Supplementary Table 1 ). Notably, λ GC was even inflated for the binary traits, which 166 we excluded from GMM so it would converge. This inflation can easily be mistaken for 167 Pragmatic metabolic heterogeneity 172 We tested for statin effect heterogeneity to assess the pragmatic value of the metabolic 173 subtypes. Using our test for large-effect covariates, only glucose had significant statin 174 heterogeneity at p = 0.05/16 (p = 1.0 × 10 −4 ); this was even clearer conditional on T2D 175 (p = 2.5 × 10 −6 ). There is no obvious FPR inflation as statin only has one other 176 significantly heterogeneous effect across other traits and K ∈ {3, 4, 5}. This is consistent 177 with statin interactions with age [38] and genetically predicted LDL [40] on T2D, and 178 also fenofibrate's interaction with lipid levels on cardiovascular risk [54] . By contrast, 179 large meta-analyses did not find inter-study statin heterogeneity [38, 39] .
180
To provide calibrated p-values, these analyses used the large-effect RGWAS test 181 where MFMR treats statin as homogeneous. This test demonstrates statin effect 182 heterogeneity in METSIM, which is further supported by tests with K = 4 and K = 5 183 (T2D-adjusted heterogeneity p = 1.2 × 10 −5 and 7.6 × 10 −4 , respectively). The p-value 184 is insignificant for K = 2, indicating insufficient resolution.
We next tested statin heterogeneity with our primary metabolic subtypes (derived 186 treating statin as heterogeneoues inside MFMR) with a heterogeneous linear regression 187 on glucose, conditioning on our standard covariates and T2D (Figure 5b) . The results 188 indicate statin increases blood sugar in most people-consistent with [38, 39] -but also 189 that it may decrease glucose in the smaller, higher-risk orange and green groups. 190 Since METSIM measured two time points, we tested the predictive value of our 191 baseline subtypes for conversion from preT2D to T2D. We fit logistic regression on time 192 2 T2D status for the 1,924 baseline prediabetics. Subtypes significantly correlated with 193 T2D conversion (p = 0.003), with orange and green converting less than blue. This 194 remained true when conditioning on our standard covariates (p = .031). This also shows 195 the subtypes persist over time, unlike prior, directly age-dependent T2D subtypes [55] . 196
Subtype-Specific Tissue Heritability Enrichment 197
Some traits, including metabolic diseases [15, 56] , have disparate genetic effects acting 198 through distinct cell types, tissues, or biological processes. Subtypes that differentiate 199 biological modes of action at this systems-level would be more easily interpretable and 200 useful for basic research and precision treatment. 201 We used LDSC-SEG to partition subtype-specific heritability across GTEx tissues 202 for several traits (Supplementary Section 5) [57] . We use a merely suggestive p = .01 203 threshold rather than attempting to account for testing multiple tissues and traits.
204
First, homogeneous subtype meta-analysis found pancreas enrichment for NMR PC 5, 205 LDL, insulin, and triglycerides (Supplementary Figure 10) . Second, heterogeneous In a purely descriptive sense, inferring subtypes is easy: applying any clustering 211 algorithm to any data produces subgroups. But existing methods cannot go beyond such 212 descriptions because they are liable to downstream FPR inflation. By contrast, RGWAS 213 is calibrated in simulation, recovers known MD subtypes, and produces biologically and 214 pragmatically validated metabolic subtypes. RGWAS handles covariates, mixed binary 215 and quantitative traits, residual trait correlations, and is implemented in the simple, free 216 rgwas R package, available with a vignette at https://github.com/andywdahl/rgwas. 217 There are several limitations to RGWAS. First, like other two step methods,
218
RGWAS fails to propagate first-step uncertainty. Similarly, although we do not imagine 219 there is a "true" K, more can always be done to better choose K. Also, while we have 220 tested a variety of simple decompositions to learn subtypes, others may perform better, 221 especially where domain-specific tools exist. In particular, MFMR is conceptually 222 similar to a matrix factorization/depth-two linear network, suggesting inner layers of 223 appropriate neural networks may define useful subtypes.
224
There are also specific limitations to our inferred stress subtypes in CONVERGE.
225
First, our stress measurements were retrospective and self-reported, meaning our stress 226 traits could be biased by MD status. Second, our analysis was not entirely without 227 domain supervision because we included the aggregate trait "Stress" that was 228 previously manually constructed [43] . interesting [58] and can clarify the interpretation of heterogeneity [59] . Or, instead, we 241 could use a continuous prior on z with a factor analysis model [22] . Finally, MFMR 242 could be applied only within diseased individuals to directly define subtypes of disease; 243 however, this requires fundamentally different step 2 tests, and subtype heterogeneity is 244 not generally disease relevant [31] .
245
Our polygenic approach to subtype validation with GxEMM provides a much needed 246 power advantage over SNP-level heterogeneity tests at the cost of resolution; 247 conceptually, polygenic risk score tests lie between [33, 60] . But SNP-level precision is 248 not needed to meet our criterion for biologically meaningful subtypes, making GxEMM 249 invaluable for subtype validation. Nonetheless, its assumed linear model can confuse 250 non-linear effects for heterogeneity. Similar issues arise in generalized linear models, as 251 the existence of effect heterogeneity depends on link function. In particular, tests for 252 differential disease heritability give different results on the liability and observed 253 scales [61, 62] , reducing confidence in our GxEMM results for T2D and CHD. Particular 254 forms of non-linearity, e.g. ascertained binary traits, can be accommodated under 255 genetic homogeneity [63] [64] [65] [66] [67] [68] , which may be extensible to heterogeneity.
256
Although we focused on fixed-and random-effect interaction tests to establish 257 heterogeneity between subtypes in step 2, it may also be useful to apply recent, 258 complementary heterogeneity tests. For example, Subtest could be used to assess 259 differences between K = 2 disease-only subtypes [31] . For large K, on the other hand, 260 StructLMM is a natural complement to GxEMM: the latter is more powerful because it 261 uses genome-wide information and a richer GxE model, but the former has SNP-level 262 resolution and scales to dramatically larger N and K. Similarly, large-K subtypes could 263 be post-processed with hierarchical clustering and tested with TreeWAS [33] . Broadly, 264 any heterogeneity test can be used in the second step, as we demonstrated with our 265 LDSC-SEG application in METSIM.
266
While we did assess tissue-specificity in our metabolic clusters in step 2, we did not 267 actively encourage subtypes to be differentiate tissues in step 1. In the future, we will 268 do this by incorporating tissue specific genetic risk scores as heterogeneous covariates 269 inside MFMR, which will allow the algorithm to prioritize tissue-specific subtypes.
270
Finally, as MFMR seeks clusters that are unaffected by confounders like population 271 structure, age or sex, it may be useful for clustering in settings where protecting certain 272 information is important for privacy or fairness [69] . In this sense, MFMR is to GMM 273 roughly as AC-PCA [70] or contrastive PCA [71] are to ordinary PCA. We derive a novel clustering algorithm, multitrait finite mixture of regressions (MFMR), 286 beginning from the standard regression model for interaction. Assuming a quantitative 287 trait y, covariates X, discrete subtypes z, and a focal covariate g putatively interacting 288 with z, the model is:
X i, is a vector of Q control covariates, like genetic PCs or sex, with homogeneous effect 290 sizes α. z i ∈ {1, . . . , K} is a K-level factor specifying the subtype for individual i, and 291 γ k are its main effects. β is the vector of subtype-specific g effects. We say g is 292 homogeneous if β 1 = . . . = β K ; otherwise, g is heterogeneous. We assume is i.i.d.
293
Gaussian with mean zero.
294
MFMR generalizes (1) in several complementary directions. First, we allow a matrix 295 of heterogeneous covariates-G instead of g. Second, we learn the subtypes (z) instead of 296 assuming they are known (giving a Finite Mixture of Regressions, FMR) by assuming z i 297 are i.i.d. Categorical:
Third, we generalize y a matrix Y of Multiple traits (MFMR), which adds power for 299 subtypes that affect the distribution of many traits. This power is crucial in practice 300 because genetic interactions are often weak.
301
Finally, we model binary traits with probit link functions to mitigate the spurious 302 local modes that plague methods like k-means. For example, this issue led others to 303 discard roughly half their data post hoc [30] . This model is computationally prohibitive 304 even for modest B, which we address with a novel conditional independence assumption. 305 This induces constraints in our optimization which we solve with block matrix identities 306 ( Supplementary Section 2.3) . 307 We fit MFMR with an Expectation Conditional-Maximization (ECM) algorithm.
308
Our ECM generalizes standard EM for Gaussian Mixture Models. Both iterate between 309 z updates in E-steps and parameter updates (e.g. α and β) in (C)M steps.
310
When fitting MFMR in step 1, a covariate that will be tested for heterogeneity in 311 step 2 can either be ignored (MFMRX), included in X (MFMR, our default), or 312 included in G (MFMR+). In Gaussian mixture models, covariates can only be ignored 313 (GMM) or added as traits (GMM+) [30] . MFMR+ and GMM+ overfit in simulations, 314 causing false positive rate (FPR) inflation ( Supplementary Figure 1) . Conversely,
315
MFMRX and GMM underfit homogeneous covariates, which also inflates FPR (Figure 316  1) . MFMR strikes a balance: the homogeneous effect is adjusted but subtypes are not 317 tuned to the heterogeneous effect. This resembles a score test as the alternate is tested 318 by fitting only the null. However, small-effect covariates, like SNPs, can be safely 319 ignored [72] , enabling genome-wide testing with MFMRX. 320 We note that MFMR generalizes several well-known models. If binary traits and X 321 are excluded and the covariates G are reduced to an intercept, MFMR becomes GMM. 322 When P = 1 and z is known, MFMR becomes a standard gene-environment interaction 323 (GxE) model with discrete environments/subtypes. Finally, if P = 1 and β k = β 0 for all 324 k, MFMR reduces to linear/probit regression.
325
RGWAS step 2: calibrated tests to validate subtypes 326
For simplicity, we assume there are K = 2 subtypes and just one interacting covariate, g. 327 These assumptions mean the output from step 1 is just a vector z, where z i is the subtype 1 probability for sample i, and that the interaction model takes a simple form: 329
X collects all background covariates, like genetic PCs, unlike existing subtype validation 330 tests that largely ignore population structure [23, 25, 28, 30] . * is element-wise 331 multiplication, but it can be generalized to allow K > 2 and a matrix G instead of a 332 single covariate g. 333 We consider three tests for g: the homogeneity test for δ = 0 given β = 0; the 334 heterogeneity test for β = 0 with free δ; and the global test for δ, β = 0 [73] . The 335 homogeneity test has 1 degree of freedom (df), the heterogeneity test has K − 1 df, and 336 the global test has K df. We focus on the heterogeneity test, which establishes that g 337 has differential effects across subtypes and thus that the subtypes differ in causal 338 biology (if g is genetic) or pragmatically (e.g. if g is a treatment). We assume is i.i.d 339 and test with linear or logistic regression. 340 We also use a polygenic version of (3), GxEMM [62] , to jointly model and test β 341 across all SNPs with random effects. GxEMM uses a predefined inter-sample genetic 342 similarity matrix [45, 74] to partition phenotypic heritability into a component shared 343 between subtypes (h 2 hom ) and subtype-specific components. GxEMM is useful for 344 genetic subtyping because the test σ 2 1 = · · · = σ 2 K = 0 is a powerful way to demonstrate 345 that subtypes have partially distinct genetic bases when sample size is too low to 346 discover individual subtype-specific SNP effects. We fit both Free GxEMM, which 347 learns specific heritabilities in each subtype (h 2 k ), and IID GxEMM, which assumes 348 subtypes have equal heritability (h 2 k = h 2 het for all k).
349
Other approaches to infer subtypes 350 We develop a novel subtyping approach by applying CCA to G and the joint binary and 351 quantitative phenotype matrix (Y b : Y ), both centered and scaled, and taking z to be 352 the top phenotypic CC. CCA (and phenotypic PCA) defines z as a linear trait 353 combination, implying its heterogeneity tests cannot be trait-specific (Supplementary 354 Section 4). Nonetheless, sparse estimators can resolve this problem in theory, and CCA 355 is computationally efficient ( Supplementary Figure 3 ). 356 We also tested GMM, which models samples as draws from one of K multivariate 357 Gaussians. We fit GMM to the quantitative traits with a standard EM algorithm [75] . 358 We consider GMM similar, in the sense of covariate-unawareness, to k-means, which 359 struggles even more with binary traits, and TDA, a proprietary package.
360
Most similar to MFMR, LIMMI aims to identify GxE with unknown E in gene 361 expression [22] . Beyond many technical differences, LIMMI and MFMR are built for 362 disjoint scenarios: MFMR only fits tens of traits, but LIMMI only fits hundreds of 363 samples, preventing its use in our setting.
364
METSIM dataset 365 We selected metabolically relevant SNPs by taking published GWAS SNPs for T2D or 366 CHD. We used the 153 T2D SNPs in Table 1 of [76] as known T2D SNPs. We had 367 genotyped 86 of these SNPs, which we reduced further to 68 roughly independent SNPs 368 (r 2 < .1). We used the 65 CHD SNPs in Supplementary Table 2 of [77] as known CHD 369 SNPs, 13 of which we genotyped (all r 2 < .1). We filtered the original 10,070 person 370 dataset so all pairwise kinships were below 0.05, as in [45] .
Phenotype imputation 372
We imputed missing data before running MFMR in CONVERGE. We jointly imputed 373 covariates and traits with a sample-wise i.i.d. Gaussian model (MVN-impute from [78] ). 374 We thresholded imputed entries in Y b to {0, 1} in order to retain the downstream 375 logistic regression framework. By contrast, discarding samples with any missing data 376 reduces sample size by roughly half and the known positive SNP interactions were no 377 longer recovered. 378 We imputed METSIM similarly, including all 228 NMR traits at the imputation step. 379 We used softImpute to accommodate the wide matrix [79] . 
